What insurance policy changes affect CPT 88305?

There are 7 tracked policy changes affecting CPT 88305, including updates from Blue Cross NC, Aetna, Florida Blue. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 88305?

Payers that have issued tracked updates for CPT 88305 include: Blue Cross NC, Aetna, Florida Blue, Blue Cross & Blue Shield of Mississippi.

How do I get notified when CPT 88305 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 88305. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 88305?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

88305 — A doctor trained in examining tissue samples under a microscope analyzes a piece of your body to identify disease or abnormalities.: Insurance Policy Changes

88305 Insurance Policy Changes

CPT 88305, in plain terms, covers A doctor trained in examining tissue samples under a microscope analyzes a piece of your body to identify disease or abnormalities. CPT 88305 is referenced in 7 tracked payer policy changes from Blue Cross NC, Aetna, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 88305 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Tumor Chemosensitivity Assays (CPB 0245, reviewed 2026-04-13)

Aetna·Effective Apr 13, 2026

Aetna is maintaining a non-coverage stance on tumor chemosensitivity assays, classifying them as experimental/investigational/unproven. This policy (CPB 0245, reviewed 2026-04-13) specifies 15+ assay types and their associated CPT codes that will not be covered, including 3D Predict assays, ChemoFx, MiCK apoptosis assay, and others. Billing teams must ensure claims for these assays are not submitted or are denied appropriately, and providers must be aware these services are patient-responsibility.

88305 Insurance Policy Changes

Medical Policy Updates August 5, 2026

Tumor Chemosensitivity Assays (CPB 0245, reviewed 2026-04-13)

Tumor Chemoresistance Assays (CPB 0758, reviewed 2025-12-02)

2026 Breast Cancer Screening Coverage Updates

OfficeLink Updates - May 2025 notices and reminders (PDF)

Anthrax (CPB 0483, reviewed 2026-07-29)

Systems Pathology in Prostate Cancer